- Home
- WNEB vs CRVS Comparison
WNEB vs CRVS Comparison
Compare WNEB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- CRVS
- Stock Information
- Founded
- WNEB 1853
- CRVS 2014
- Country
- WNEB United States
- CRVS United States
- Employees
- WNEB N/A
- CRVS N/A
- Industry
- WNEB Savings Institutions
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- CRVS Health Care
- Exchange
- WNEB Nasdaq
- CRVS Nasdaq
- Market Cap
- WNEB 165.5M
- CRVS 161.4M
- IPO Year
- WNEB N/A
- CRVS 2016
- Fundamental
- Price
- WNEB $8.67
- CRVS $4.94
- Analyst Decision
- WNEB Hold
- CRVS Buy
- Analyst Count
- WNEB 4
- CRVS 3
- Target Price
- WNEB $8.50
- CRVS $5.75
- AVG Volume (30 Days)
- WNEB 39.9K
- CRVS 345.2K
- Earning Date
- WNEB 10-22-2024
- CRVS 11-05-2024
- Dividend Yield
- WNEB 3.28%
- CRVS N/A
- EPS Growth
- WNEB N/A
- CRVS N/A
- EPS
- WNEB 0.63
- CRVS N/A
- Revenue
- WNEB $74,435,000.00
- CRVS N/A
- Revenue This Year
- WNEB N/A
- CRVS N/A
- Revenue Next Year
- WNEB $5.16
- CRVS N/A
- P/E Ratio
- WNEB $13.47
- CRVS N/A
- Revenue Growth
- WNEB N/A
- CRVS N/A
- 52 Week Low
- WNEB $6.00
- CRVS $1.05
- 52 Week High
- WNEB $9.25
- CRVS $4.87
- Technical
- Relative Strength Index (RSI)
- WNEB 60.39
- CRVS 68.45
- Support Level
- WNEB $8.51
- CRVS $3.90
- Resistance Level
- WNEB $8.99
- CRVS $4.87
- Average True Range (ATR)
- WNEB 0.18
- CRVS 0.33
- MACD
- WNEB -0.05
- CRVS -0.01
- Stochastic Oscillator
- WNEB 46.67
- CRVS 80.38
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).